Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function
Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
1. Ticagrelor inhibits inflammation and improves vascular endothelial cell function to a
greater extent than clopidogrel in ST-segment elevation myocardial infarction(STEMI)
patients receiving percutaneous coronary intervention.
2. Ticagrelor can reduce the serum levels of inflammatory biomarkers both in coronary and
in peripheral venous in patients with ST-segment elevation myocardial infarction(STEMI).